Please use this identifier to cite or link to this item:
Title: Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor
Author: Sureda, Anna
Chabannon, Christian
Masszi, Tamás
Pohlreich, David
Scheid, Christof
Thieblemont, Catherine
Wahlin, Björn E.
Sakellari, Ioanna
Russell, Nigel
Janikova, Andrea
Dabrowska-Iwanicka, Anna
Touzeau, Cyrille
Esquirol, Albert
Jantunen, Esa
van der Werf, Steffie
Bosman, Paul
Boumendil, Ariane
Liu, Qianying
Celanovic, Marina
Montoto, Silvia
Dreger, Peter
Keywords: Limfomes
Cèl·lules mare
Stem cells
Issue Date: 2020
Publisher: Macmillan Publishers Limited
Abstract: Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.
Note: Reproducció del document publicat a:
It is part of: Bone Marrow Transplantation, 2020, vol. 55, p. 613-622
Related resource:
ISSN: 0268-3369
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
694442.pdf856.33 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons